All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in mantle cell lymphoma (MCL)?
Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?
To answer this question, Phillips describes a phase I trial investigating complete response rate and minimal residual disease (MRD) detectability when using this triplet regimen in untreated patients with MCL.
Updated NCCN Guidelines for HL, FL and MCL
The NCCN has updated its guidelines for several lymphoma subtypes in light of the new 2016 WHO classifications for Mature B-Cell, T-Cell, and NK-Cell conditions
Is a response-adapted treatment strategy feasible for patients with MCL?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Mats Jerkeman, Lund University, Lund, SE. We asked, Is a...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox